BACKGROUND: As dihydrotestosterone (DHT) is the most potent androgen in the prostate, inhibition of the 5alpha-reductase isoenzymes, which convert testosterone to DHT, could be an appropriate target for the treatment of prostate cancer. METHODS:Eighty-one men with clinically localized prostate cancer received daily dutasteride 3.5 or 0.5 mg, or no therapy for 4 months before radical prostatectomy. Histopathological assessments were conducted on prostatectomy specimens. RESULTS: Treatment with dutasteride was associated with reductions in serum and intraprostatic DHT of >or=90%, and a decrease in total prostate and tumor volumes. No effect of dutasteride was noted on Gleason grade. Histopathological effects on benign tissue were similar but less prominent than those seen with androgen ablation, whereas there was no significant difference in cancer histology among the groups. CONCLUSIONS:Dutasteride treatment results in similar but less marked changes compared with androgen ablation.
RCT Entities:
BACKGROUND: As dihydrotestosterone (DHT) is the most potent androgen in the prostate, inhibition of the 5alpha-reductase isoenzymes, which convert testosterone to DHT, could be an appropriate target for the treatment of prostate cancer. METHODS: Eighty-one men with clinically localized prostate cancer received daily dutasteride 3.5 or 0.5 mg, or no therapy for 4 months before radical prostatectomy. Histopathological assessments were conducted on prostatectomy specimens. RESULTS: Treatment with dutasteride was associated with reductions in serum and intraprostatic DHT of >or=90%, and a decrease in total prostate and tumor volumes. No effect of dutasteride was noted on Gleason grade. Histopathological effects on benign tissue were similar but less prominent than those seen with androgen ablation, whereas there was no significant difference in cancer histology among the groups. CONCLUSIONS:Dutasteride treatment results in similar but less marked changes compared with androgen ablation.
Authors: John K Amory; Mark A Bush; Hui Zhi; Ralph B Caricofe; Alvin M Matsumoto; Ronald S Swerdloff; Christina Wang; Richard V Clark Journal: J Urol Date: 2010-12-18 Impact factor: 7.450
Authors: Diping Wang; R Bruce Montgomery; Lucy J Schmidt; Elahe A Mostaghel; Haojie Huang; Peter S Nelson; Donald J Tindall Journal: Cancer Res Date: 2009-12-15 Impact factor: 12.701
Authors: Khalid Z Masoodi; Raquel Ramos Garcia; Laura E Pascal; Yujuan Wang; Hei M Ma; Katherine O'Malley; Kurtis Eisermann; Daniel H Shevrin; Holly M Nguyen; Robert L Vessella; Joel B Nelson; Rahul A Parikh; Zhou Wang Journal: Endocrinology Date: 2013-05-13 Impact factor: 4.736